Trial · NCT03124459
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1-Open Label Dose Escalation | STARTED | Part 1 Cohort 1 (150 mg) | 6 | |
| Part 1-Open Label Dose Escalation | STARTED | Part 1 Cohort 2 (200 mg) | 6 | |
| Part 1-Open Label Dose Escalation | STARTED | Part 1 Cohort 3 (240 mg) | 6 | |
| Part 1-Open Label Dose Escalation | STARTED | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 0 | |
| Part 1-Open Label Dose Escalation | STARTED | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 0 | |
| Part 1-Open Label Dose Escalation | STARTED | Part 2 (Open-label) ACE-083 Arm | 0 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 1 Cohort 1 (150 mg) | 6 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 1 Cohort 2 (200 mg) | 6 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 1 Cohort 3 (240 mg) | 6 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 0 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 0 | |
| Part 1-Open Label Dose Escalation | COMPLETED | Part 2 (Open-label) ACE-083 Arm | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 1 Cohort 1 (150 mg) | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 1 Cohort 2 (200 mg) | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 1 Cohort 3 (240 mg) | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 0 | |
| Part 1-Open Label Dose Escalation | NOT COMPLETED | Part 2 (Open-label) ACE-083 Arm | 0 | |
| Phase 2- Randomized Doubled-blind | STARTED | Part 1 Cohort 1 (150 mg) | 0 | |
| Phase 2- Randomized Doubled-blind | STARTED | Part 1 Cohort 2 (200 mg) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03124459/flow